Spiral Therapeutics is a technology company.
Spiral Therapeutics has raised $6.0M across 1 funding round.
Spiral Therapeutics has raised $6.0M in total across 1 funding round.
Spiral Therapeutics has raised $6.0M in total across 1 funding round.
Spiral Therapeutics's investors include Catalio Capital, Inveready Technology Investment Group.
Spiral Therapeutics is a clinical-stage pharmaceutical company developing novel therapies for inner ear disorders, including hearing loss and balance issues like Meniere's Disease.[1][2][4] It builds a pipeline of advanced treatments using proprietary drug delivery technologies inspired by ophthalmology, targeting unmet needs in neurotology where no approved therapies exist; its lead product, SPT-2101, is a sustained-release steroid formulation for inner ear inflammation, delivered minimally invasively to the cochlea.[1][4][5] The company serves patients with conditions such as hearing loss and vertigo, solving problems of ineffective drug exposure in the inner ear through precise, durable administration; it has raised $8.3M across two funding rounds, with recent investment from Esperante Ventures and Ferring Ventures supporting expanded trials, and employs under 25 people in South San Francisco.[1][4]
Growth momentum includes completing enrollment in an open-label Australian trial for SPT-2101 showing safety, reduced vertigo, and superior pharmacokinetics, followed by a randomized placebo-controlled expansion; plans include an IND submission for US pivotal trials by late 2024 after acquiring Otonomy assets.[1][4]
Spiral Therapeutics was founded in early 2016 by Hugo Peris, Justin S. Hanes, and Eugene de Juan, drawing inspiration from ophthalmology to address inner ear challenges.[1][3] Headquartered in South San Francisco, the company launched with a focus on proprietary therapeutics and drug delivery for hearing loss, entering the clinic with lead candidate LPT99 (targeting APAF1 for hearing loss) in December 2018.[1][3] Pivotal early traction came from building a pipeline amid no approved treatments, recent funding to advance SPT-2101 (for Meniere's Disease), and asset acquisition from Otonomy, positioning it as a neurotology leader under CEO Hugo Peris.[3][4]
Spiral rides the wave of neurotology innovation, targeting inner ear disorders affecting millions amid aging populations and no FDA-approved local therapies, leveraging biotech advances in sustained-release delivery akin to ophthalmology successes.[1][2][4] Timing aligns with rising demand for non-surgical hearing/balance treatments, bolstered by post-pandemic focus on sensory health and M&A activity like Otonomy's assets enabling faster US trials.[4] Market forces include large unmet needs (e.g., Meniere's vertigo, sensorineural hearing loss) and investor interest in precision pharma platforms; Spiral influences the ecosystem by pioneering cochlear access, potentially unlocking a pipeline for balance/hearing disorders and inspiring similar drug-device hybrids.[1][3][5]
Spiral Therapeutics is poised to lead inner ear therapeutics, with SPT-2101's US pivotal trials via late-2024 IND submission as the key catalyst, potentially yielding first approvals in neurotology.[4] Trends like AI-optimized drug delivery, expanded gene therapies for hearing, and global trial acceleration will shape its path, amplifying influence through partnerships and pipeline growth (e.g., LPT99, BN-119).[3] As a nimble clinical-stage player with proven safety data, expect scaled funding, board expertise driving commercialization, and broader impact on protecting hearing—cementing its role from pipeline builder to market pioneer.[1][4]
Spiral Therapeutics has raised $6.0M across 1 funding round. Most recently, it raised $6.0M Series A in December 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2018 | $6.0M Series A | Catalio Capital, Inveready Technology Investment Group |